Theravance Biopharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.3M
Doctors Paid
2,890
Transactions
12,602
2018 Total
$5.8M
Payment Breakdown by Category
Research$20.1M (90.3%)
Consulting$1.1M (5.1%)
Travel$271,245 (1.2%)
Food & Beverage$261,332 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20.1M | 2,406 | 90.3% |
| Consulting Fee | $1.1M | 399 | 5.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $474,443 | 247 | 2.1% |
| Travel and Lodging | $271,245 | 568 | 1.2% |
| Food and Beverage | $261,332 | 8,637 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $23,450 | 19 | 0.1% |
| Education | $1,982 | 326 | 0.0% |
Payments by Type
Research
$20.1M
2,405 transactions
General
$2.2M
10,196 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 0128 TD-4208 | $4.3M | 6 | 931 |
| 0149_PIFR | $1.5M | 1 | 248 |
| Protocol #0112 | $1.5M | 1 | 175 |
| TD-5108 | $1.2M | 0 | 146 |
| 0126 TD-4208 | $1.2M | 1 | 92 |
| TOUR 1-7X84ZY | $1.2M | 2 | 141 |
| PRIZM.1439.PH1 | $1.2M | 0 | 14 |
| 99 | $981,137 | 1 | 207 |
| 0127 TD-4208 | $891,772 | 0 | 76 |
| 28-day Parallel Group Safety Study of Revefenacin in COPD | $887,599 | 1 | 37 |
| 145 | $748,947 | 0 | 3 |
| 152 | $708,443 | 0 | 5 |
| IRB 160586 | $467,830 | 0 | 3 |
| Phase 3 Randomized Double-Blind Double-Dummy Parallel-Group Study to Compare Once Daily Nebulized Revefenacin with Spiriva | $416,758 | 1 | 69 |
| TBPH0144 | $412,853 | 1 | 40 |
| Phase 2 TD-9855 Neurogenic Orthostatic Hypotension | $387,858 | 0 | 5 |
| Study VUMC57544 | $306,358 | 0 | 1 |
| 0120 TOUR | $167,464 | 2 | 35 |
| Phase 3b 28-day Randomized Active Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenancin | $154,628 | 1 | 23 |
| Protocol 0174 | $148,409 | 0 | 1 |
| A Study of the Mechanism of Televancin Resistance | $146,756 | 0 | 2 |
| Phase 1, Fixed-Sequence, Open-label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine, Cigarette Smokign and Itraconazole on the Pharmacokinetics of TD-9855 | $92,560 | 0 | 1 |
| Treatment of COPD | $85,273 | 0 | 8 |
| PRIZM.0714.PH1 | $76,995 | 0 | 3 |
| Study 126523 Pharmacokinetics and Tolerability of TLVN | $75,757 | 0 | 1 |
| Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate Safety and Tolerability of Nebulized Revefenacin adminstersed before Nebulized Formoterol Fumarate | $75,018 | 1 | 15 |
| TD-9855 0145 | $74,440 | 0 | 1 |
| MARIN.9855.PH2 | $68,902 | 0 | 3 |
| Pharmacokinetics and Tolerability of Telavancin in Cystic Fibrosis | $55,757 | 0 | 1 |
| Phase 2 Efficacy study in subjects with Crohn's Disease | $35,410 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. Mobolaji Ogunsakin, M.d, M.D | Internal Medicine | Warner Robins, GA | $8,773 | $0 |
| Amit Gangoli, Md, MD | Infectious Disease | Limerick, PA | $8,764 | $0 |
| Stefan Schneider, Md, MD | Infectious Disease | Long Beach, CA | $8,671 | $0 |
| Braden Kuo, M.d, M.D | Gastroenterology | New York, NY | $8,618 | $0 |
| Dr. Donald Mahler, M.d, M.D | Pulmonary Disease | Lebanon, NH | $8,134 | $0 |
| Dr. Rish Pai, Md, MD | Clinical Pathology/Laboratory Medicine | Scottsdale, AZ | $8,100 | $0 |
| Dr. James Donohue, Md, MD | Pulmonary Disease | Chapel Hill, NC | $7,845 | $0 |
| Vipul Desai, Md, MD | Infectious Disease | The Woodlands, TX | $7,644 | $0 |
| Casmiar Nwaigwe, Md, MD | Infectious Disease | Minot, ND | $7,486 | $0 |
| Tariq Mehmood, Md, MD | Internal Medicine | Louisville, KY | $7,408 | $0 |
| Dr. Thuan Le, M.d, M.D | Infectious Disease | Murrieta, CA | $7,369 | $0 |
| Steven Bobula, Md, MD | Infectious Disease | Westerville, OH | $7,290 | $0 |
| Deepthi Jayasekara, Md, MD | Infectious Disease | Claremont, CA | $7,096 | $0 |
| Gerardo Negron, Md, MD | Infectious Disease | Shreveport, LA | $6,957 | $0 |
| Charles Mbonu, Md, MD | Infectious Disease | Texarkana, TX | $6,776 | $0 |
| Ashraf Elsayegh, Md, MD | Sleep Medicine | Los Angeles, CA | $6,758 | $0 |
| Gilberto Torres-Madriz, Md, MD | Infectious Disease | Miami, FL | $6,575 | $0 |
| Gil Yosipovitch, Md, MD | Dermatology | Miami, FL | $6,453 | $0 |
| Aamina Akhtar, Md, MD | Infectious Disease | St. Louis, MO | $6,395 | $0 |
| Scott Rojas, M.d, M.D | Infectious Disease | Panama City, FL | $6,334 | $0 |
| Dhaval Shah, Md, MD | Student in an Organized Health Care Education/Training Program | Newark, DE | $6,309 | $0 |
| Dr. Jamie Dwyer, M.d, M.D | Nephrology | Nashville, TN | $6,283 | $0 |
| Tuba Esfandyari, M.d, M.D | Gastroenterology | Kansas City, KS | $6,107 | $0 |
| Phillip Low, M.d, M.D | Neurology | Rochester, MN | $5,966 | $0 |
| Dr. Mario Castro, Md, MD | Critical Care Medicine | Kansas City, KS | $5,861 | $0 |
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc. has made $22.3M in payments to 2,890 healthcare providers, recorded across 12,602 transactions in the CMS Open Payments database. In 2018, the company paid $5.8M. The top product by payment volume is VIBATIV ($2.6M).
Payments were distributed across 85 medical specialties. The top specialty by payment amount is Infectious Disease ($836,991 to 846 doctors).
Payment categories include: Food & Beverage ($261,332), Consulting ($1.1M), Research ($20.1M), Travel & Lodging ($271,245).
Theravance Biopharma, Inc. is associated with 1 products in the CMS Open Payments database.